Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by

Investment analysts at began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other equities research analysts have also recently commented on the company. William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd. Craig Hallum lowered their price objective on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a research report on Monday, April 1st.

Check Out Our Latest Analysis on Accelerate Diagnostics

Accelerate Diagnostics Stock Down 0.9 %

Shares of Accelerate Diagnostics stock opened at $1.14 on Tuesday. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $8.72. The company has a 50-day simple moving average of $1.15 and a 200 day simple moving average of $1.43. The stock has a market capitalization of $25.14 million, a P/E ratio of -0.28 and a beta of 0.57.

Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.16). The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $3.00 million. On average, equities analysts anticipate that Accelerate Diagnostics will post -2.37 earnings per share for the current year.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. boosted its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) by 11.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,354,254 shares of the medical research company’s stock after buying an additional 134,530 shares during the period. Griffin Asset Management Inc. owned approximately 6.25% of Accelerate Diagnostics worth $1,341,000 as of its most recent filing with the SEC. 17.14% of the stock is owned by institutional investors and hedge funds.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Read More

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with's FREE daily email newsletter.